Associated Papers
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
41167083 (PubMed )
Supplement: mmc4.xlsx › Table_S10B
Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma.
Ko JM et al.
British Journal of Cancer, 2025
Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
Iwasaki T et al.
Cancer Science, 2024
Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer.
Liu J et al.
Global Medical Genetics, 2024
38628662 (PubMed )
Supplement: 10-1055-s-0044-1786004-s2400018.pdf
Genomic profiles of renal cell carcinoma in a small Chinese cohort.
Tai S et al.
Frontiers in Oncology, 2023
37427096 (PubMed )
Supplement: Table_1.xls › Sheet1
Functional polymorphisms in Nrf2: implications for human disease.
Cho HY et al.
Free Radical Biology & Medicine, 2015
Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.
Cho HY
Oxidative Medicine and Cellular Longevity, 2013
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Shibata T et al.
Neoplasia (new York, N.y.), 2011
Select a paper to view details